A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and
paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant
Ovarian Cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics